Brief: Novo's Sogroya Gets Positive CHMP Opinion In Europe For Children With ISS
18/09/2026 11:40
BRIEF-Novo's Sogroya Gets Positive CHMP Opinion In Europe For Children With ISS Sept 18 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO’S ONCE-WEEKLY SOGROYA® (SOMAPACITAN) RECEIVES POSITIVE CHMP OPINION IN EUROPE FOR CHILDREN WITH IDIOPATHIC SHORT STATURE (UNEXPLAINED SHORTNESS)
Source text: ID:nGNEb3whbw
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals